ResultsPatients into 2 groups when the baseline group difference was not statistically significant, comparable.
结果两组患者入组时的基线情况差异无统计学意义，具有可比性。
At one year, 32% of patients in the bevacizumab group gained 15 or more letters from baseline visual acuity compared with 3% in the standard care group.
第一年，进行贝伐单抗注射的32%的患者的可认字母增加了15个，而标准治疗方案组的患者增加了3%。
Even as smartphones (with E-mail and web capabilities) become more popular, SMS remains the baseline of mobile digital communication, and permeates nearly every social group.
即使智能手机(具备电邮和联网的能力)越来越流行，手机短信仍是移动数字通信的基本，几乎渗透到每一个社会群体。
BMD at 48 months was strongly correlated with baseline, but women who had received denosumab maintained higher BMD than the placebo group.
在第48个月，骨密度与基线高度相关，但经过狄诺塞麦治疗的妇女骨密度一直高于安慰剂组。
On day 14, 17 percent of subjects in this group had reductions from baseline greater than 2.0 log10.
在日子，在这一个团体的14,17 %的主题让了来自基线的减少比2.0个记录10大。
The etanercept group showed a greater percent change in C-peptide area under the curve from baseline to week 24 (39% increase in etanercept group versus 20% decrease in placebo group;
从基准到第24周C -肽曲线下面积依那西普组表现出较大变化（ 依那西普组增加39 ％与安慰剂组下降20 ％；
Method 568 rural cooks from Jiangsu province were investigated as baseline population, and among them 269 rural cooks were in control group and 299 rural cooks in intervention group.
方法在江苏地区调查民间厨师568人，作为基线调查人群，其中对照组269人，干预组299人。
At baseline, 81% of patients in the BTX-A group were experiencing urgent urinary incontinence daily, but urinary frequency normalized in 57% at 4 weeks, and 36% maintained this benefit at 24 weeks;
BTX-A组81%的患者试验初始时每天急迫性尿失禁，而在4周时57%的患者尿频改善到正常，36%的患者在24周时仍保持得到改善。
The original trial of which the folic acid study was a part began in late 1994 when 11,280 women were enrolled in a run-in; baseline blood samples were collected from 72% of the group.
最初对于叶酸研究的部分实验始于1994年末，当时研究人员对11,280名妇女进行了非正式调查，并采集了其中72%人的血样作为原始血液样本。
RESULTS: Compared with baseline, HR in group C were significantly lower(P0.05).
结果：C组注药后血压、心率均较基础值显著降低（P0.05）；
Percent reduction from baseline of inflammatory lesions at week 4 were 40.9% in the metronidazole group and 10.7% in the vehicle group;
对炎性损害较治疗前减少百分数，在治疗的第4周甲硝唑组为40.9％，安慰剂组为10.7％；
Percent reduction from baseline of inflammatory lesions at week 4 were 40.9% in the metronidazole group and 10.7% in the vehicle group;
对炎性损害较治疗前减少百分数，在治疗的第4周甲硝唑组为40.9％，安慰剂组为10.7％；
应用推荐